http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 13 Aug 2025 08:03:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html <p>Alto Neuroscience Inc. (NYSE: ANRO) appointed Raymond Sanchez, M.D., to its board of directors, effective August 12, 2025, according to a company statement.</p> <p>Sanchez brings more than 20 years of experience in the life sciences industry. He currently serves as a senior advisor at Bain Capital Life Sciences since September 2024. Previously, he worked as chief medical officer at Cerevel Therapeutics Holdings Inc. from January 2019 until the company's acquisition by AbbVie Inc. in August 2024.</p> <p>From November 2007 to January 2019, Sanchez held various positions at Otsuka Pharmaceutical Development & Commercialization Inc., most recently as senior vice president of global clinical http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Raymond+Sanchez+to+board+of+directors/25192529.html Wed, 13 Aug 2025 08:03:09 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. </p><p> “We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Appoints+Biotech+Industry+Veteran%2C+Raymond+Sanchez%2C+M.D.%2C+to+Its+Board+of+Directors/25192526.html Wed, 13 Aug 2025 08:03:00 -0400 A.04564592 A.09408455 A.19520801 A.32790785 A.50114162 ANRO CERE O.00005399 O.00915600 O.02823430 O.22431884 O.50267127 RAPP